INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Inclusion Criteria

• •Men and women, aged 18 years or older on the day of signing the Informed Consent Form (ICF).
• •Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.
• •Participants with DLBCL, MZL or MCL must have received at least 1 prior line of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.
• •Participants with FL must have received at least 2 prior lines of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.
• •Ineligible for stem cell transplant.
• •Participants with DLBCL must have failed or refused stem cell transplantation or failed first-line salvage therapy if ineligible for transplantation.
• •Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.
• •Life expectancy of \> 3 months.
• •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 (see Appendix D).
• •Willingness to avoid pregnancy or fathering a child.
• •Ability to comprehend and willingness to sign an ICF
• •* Did not discontinue because of tolerability concerns.
• •* Achieved either partial response (PR) or complete response (CR) to the bendamustine regimen of at least 12 months in duration before relapse/progression.
• •* Experienced progression following a regimen containing an alkylating agent.
• •For participants to be treated with ibrutinib (Treatment C), prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor.
• •Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.
• •Active graft-versus-host disease following allogeneic transplant.
• •Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.